Difficulty: Medium
Average Score: 73%
Practice
A 12-year-old boy with obsessive-compulsive disorder and depression desires to be managed with a single pharmacologic agent. Which of the following agents would be best used in this patient?
Correct answer
C
Rationale
In the case of a 12-year-old boy with obsessive-compulsive disorder and depression who desires a single pharmacologic agent for management, the best choice would be option C) Fluvoxamine. This is because Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is FDA-approved for the treatment of obsessive-compulsive disorder in pediatric patients. It has shown efficacy in managing both OCD and depression symptoms in children and adolescents.
Option A) Bupropion is not typically used as a first-line treatment for OCD and depression in pediatric patients. It is more commonly prescribed for conditions like major depressive disorder and smoking cessation.
Option B) Fluoxetine is another SSRI commonly used to treat depression and OCD in children. While it is effective, fluvoxamine is preferred in this case due to its specific FDA approval for pediatric OCD.
Option D) Mirtazapine is not typically the first choice for treating OCD in children. It is more commonly used for depression in adults due to its sedating properties.
In an educational context, understanding the specific pharmacologic agents approved for use in pediatric patients with various conditions is crucial for healthcare providers working with children and adolescents. Being aware of the nuances in drug selection based on age, diagnosis, and FDA approvals ensures safe and effective treatment interventions for young patients with mental health disorders.
Option A) Bupropion is not typically used as a first-line treatment for OCD and depression in pediatric patients. It is more commonly prescribed for conditions like major depressive disorder and smoking cessation.
Option B) Fluoxetine is another SSRI commonly used to treat depression and OCD in children. While it is effective, fluvoxamine is preferred in this case due to its specific FDA approval for pediatric OCD.
Option D) Mirtazapine is not typically the first choice for treating OCD in children. It is more commonly used for depression in adults due to its sedating properties.
In an educational context, understanding the specific pharmacologic agents approved for use in pediatric patients with various conditions is crucial for healthcare providers working with children and adolescents. Being aware of the nuances in drug selection based on age, diagnosis, and FDA approvals ensures safe and effective treatment interventions for young patients with mental health disorders.